Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueDepreciation ExpenseEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - Net
Ratios

Vanda Pharmaceuticals (VNDA) Accumulated Depreciation & Amortization (2016 - 2025)

Vanda Pharmaceuticals' Accumulated Depreciation & Amortization history spans 14 years, with the latest figure at $11.6 million for Q4 2024.

  • For Q4 2024, Accumulated Depreciation & Amortization rose 3.45% year-over-year to $11.6 million; the TTM value through Dec 2024 reached $11.6 million, up 3.45%, while the annual FY2024 figure was $11.6 million, 3.45% up from the prior year.
  • Accumulated Depreciation & Amortization for Q4 2024 was $11.6 million at Vanda Pharmaceuticals, up from $11.2 million in the prior quarter.
  • Across five years, Accumulated Depreciation & Amortization topped out at $11.6 million in Q4 2024 and bottomed at $8.0 million in Q4 2020.
  • The 5-year median for Accumulated Depreciation & Amortization is $10.4 million (2022), against an average of $10.1 million.
  • The largest annual shift saw Accumulated Depreciation & Amortization increased 21.42% in 2020 before it grew 3.45% in 2024.
  • A 5-year view of Accumulated Depreciation & Amortization shows it stood at $8.0 million in 2020, then rose by 16.8% to $9.4 million in 2021, then rose by 11.11% to $10.4 million in 2022, then rose by 7.31% to $11.2 million in 2023, then rose by 3.45% to $11.6 million in 2024.
  • Per Business Quant, the three most recent readings for VNDA's Accumulated Depreciation & Amortization are $11.6 million (Q4 2024), $11.2 million (Q4 2023), and $10.4 million (Q4 2022).